Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Policresulen + cinchocaine hydrochloride is a fixed-dose combination topical therapy primarily used in proctology for the treatment of hemorrhoids and other anorectal conditions. Policresulen is a polycondensation product of metacresolsulfonic acid and formaldehyde that acts as a selective hemostatic and antiseptic agent; it works by coagulating necrotic or pathologically altered tissue while leaving healthy tissue intact, thereby promoting wound healing and preventing infection. Cinchocaine hydrochloride (also known as dibucaine) is a potent, long-acting local anesthetic of the amide type that provides symptomatic relief from pain and itching by blocking the initiation and conduction of nerve impulses through the inhibition of voltage-gated sodium channels. The combination is typically available as an ointment or suppository for rectal or perianal application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on policresulen + cinchocaine hydrochloride.